{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:51:05Z","timestamp":1792281065498,"version":"4.4.0"},"reference-count":275,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.phrs.2017.05.020","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T00:50:40Z","timestamp":1496191840000},"page":"57-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"special_numbering":"PA","title":["Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease"],"prefix":"10.1016","volume":"125","author":[{"given":"Carlos M.","family":"Ferrario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam E.","family":"Mullick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.phrs.2017.05.020_bib0005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"49","key":"10.1016\/j.phrs.2017.05.020_bib0010","doi-asserted-by":"crossref","first-page":"15078","DOI":"10.1073\/pnas.1518393112","article-title":"Rising morbidity and mortality in midlife among white non-hispanic Americans in the 21st century","volume":"112","author":"Case","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.05.020_bib0015","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"American heart association statistics, S. stroke statistics, heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1291\/hypres.22.147","article-title":"Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics","volume":"22","author":"Timmermans","year":"1999","journal-title":"Hypertens. Res."},{"issue":"Suppl. 5","key":"10.1016\/j.phrs.2017.05.020_bib0025","first-page":"S3","article-title":"Discovery of losartan, the first angiotensin II receptor antagonist","volume":"9","author":"Timmermans","year":"1995","journal-title":"J. Hum. Hypertens."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10557-012-6380-6","article-title":"Renin inhibitors and cardiovascular and renal protection: an endless quest?","volume":"27","author":"Azizi","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"11","key":"10.1016\/j.phrs.2017.05.020_bib0035","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.phrs.2017.05.020_bib0040","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0045","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.250","article-title":"Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances","volume":"17","author":"McMurray","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2017.05.020_bib0050","first-page":"57s","article-title":"The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertension","author":"Gavras","year":"1975","journal-title":"Clin. Sci. Mol. Med."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0055","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCRESAHA.116.302706","article-title":"Role of mineralocorticoid receptor antagonists in cardiovascular disease","volume":"116","author":"Ferrario","year":"2015","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0065","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCRESAHA.110.238550","article-title":"Translational success stories: angiotensin receptor 1 antagonists in heart failure","volume":"109","author":"Dell'Italia","year":"2011","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.phrs.2017.05.020_bib0070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0000605-200912150-00162","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease","volume":"151","author":"Baker","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2017.05.020_bib0075","doi-asserted-by":"crossref","first-page":"j4","DOI":"10.1136\/bmj.j4","article-title":"Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials","volume":"356","author":"Bangalore","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/jhh.2009.34","article-title":"Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study","volume":"24","author":"Blacher","year":"2010","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.phrs.2017.05.020_bib0085","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijcard.2014.11.179","article-title":"Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: a number-needed-to-treat analysis","volume":"181","author":"Brugts","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1753944716644131","article-title":"Mega clinical trials which have shaped the RAS intervention clinical practice","volume":"10","author":"Dusing","year":"2016","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0095","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1753944716642677","article-title":"Cardiac remodelling and RAS inhibition","volume":"10","author":"Ferrario","year":"2016","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0100","doi-asserted-by":"crossref","first-page":"H404","DOI":"10.1152\/ajpheart.00219.2016","article-title":"Intracrine angiotensin II functions originate from noncanonical pathways in the human heart","volume":"311","author":"Ferrario","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2017.05.020_bib0105","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-017-0708-3","article-title":"Novel cardiac intracrine mechanisms based on ang- (1\u201312)\/chymase axis requires a revision of therapeutic approaches in human heart disease","author":"Reyes","year":"2017","journal-title":"Curr. Hypertens. Rep."},{"issue":"22","key":"10.1016\/j.phrs.2017.05.020_bib0110","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1016\/0006-2952(88)90614-4","article-title":"Formation of angiotensin II and other angiotensin peptides from des-leu 10-angiotensin I in rat lung and kidney","volume":"37","author":"Drummer","year":"1988","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0006-2952(90)90058-S","article-title":"Effect of chronic enalapril treatment on enzymes responsible for the catabolism of angiotensin I and formation of angiotensin II","volume":"39","author":"Drummer","year":"1990","journal-title":"Biochem. Pharmacol."},{"issue":"Suppl. 5","key":"10.1016\/j.phrs.2017.05.020_bib0120","first-page":"III126","article-title":"Angiotensin-(1\u20137): a new hormone of the angiotensin system","volume":"18","author":"Ferrario","year":"1991","journal-title":"Hypertension"},{"issue":"3 Pt 2","key":"10.1016\/j.phrs.2017.05.020_bib0125","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/01.HYP.30.3.535","article-title":"Counterregulatory actions of angiotensin-(1\u20137)","volume":"30","author":"Ferrario","year":"1997","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/01.ATV.0000253889.09765.5f","article-title":"Mass-spectrometric identification of a novel angiotensin peptide in human plasma","volume":"27","author":"Jankowski","year":"2007","journal-title":"Arterioscler. Thromb Vasc. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2017.05.020_bib0135","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","article-title":"Discovery and characterization of alamandine: a novel component of the renin-angiotensin system","volume":"112","author":"Lautner","year":"2013","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbrc.2013.10.124","article-title":"Big angiotensin-25: a novel glycosylated angiotensin-related peptide isolated from human urine","volume":"441","author":"Nagata","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0145","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bbrc.2006.09.146","article-title":"Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system","volume":"350","author":"Nagata","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/1753944715574817","article-title":"Roles of collecting duct renin and (pro)renin receptor in hypertension: mini review","volume":"9","author":"Gonzalez","year":"2015","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/HYPERTENSIONAHA.110.163519","article-title":"Intratubular renin-angiotensin system in hypertension","volume":"57","author":"Navar","year":"2011","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0160","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.coph.2011.01.009","article-title":"Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension","volume":"11","author":"Navar","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11906-014-0429-9","article-title":"Angiotensin-(1\u201312): a chymase-mediated cellular angiotensin II substrate","volume":"16","author":"Ahmad","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib0170","doi-asserted-by":"crossref","first-page":"H2242","DOI":"10.1152\/ajpheart.00175.2008","article-title":"Angiotensin-(1\u201312) is an alternate substrate for angiotensin peptide production in the heart","volume":"294","author":"Trask","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4 Pt 2","key":"10.1016\/j.phrs.2017.05.020_bib0175","first-page":"H1769","article-title":"Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations","volume":"273","author":"Balcells","year":"1997","journal-title":"Am. J. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0180","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00001573-200207000-00009","article-title":"Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases","volume":"17","author":"Dell'Italia","year":"2002","journal-title":"Curr. Opin. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0185","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.RES.66.4.883","article-title":"Angiotensin II-forming pathways in normal and failing human hearts","volume":"66","author":"Urata","year":"1990","journal-title":"Circ. Res."},{"issue":"36","key":"10.1016\/j.phrs.2017.05.020_bib0190","doi-asserted-by":"crossref","first-page":"22348","DOI":"10.1016\/S0021-9258(18)45712-2","article-title":"Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart","volume":"265","author":"Urata","year":"1990","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.phrs.2017.05.020_bib0195","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1042\/CS20130400","article-title":"An evolving story of angiotensin-II-forming pathways in rodents and humans","volume":"126","author":"Ferrario","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0200","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbrc.2016.07.100","article-title":"Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1\u201312) metabolizing enzyme","volume":"478","author":"Ahmad","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0205","doi-asserted-by":"crossref","first-page":"H2614","DOI":"10.1152\/ajpheart.91521.2007","article-title":"Localization of the novel angiotensin peptide, angiotensin-(1\u201312), in heart and kidney of hypertensive and normotensive rats","volume":"294","author":"Jessup","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"8","key":"10.1016\/j.phrs.2017.05.020_bib0210","doi-asserted-by":"crossref","first-page":"H995","DOI":"10.1152\/ajpheart.00833.2015","article-title":"Cardiac angiotensin-(1\u201312) expression and systemic hypertension in rats expressing the human angiotensinogen gene","volume":"310","author":"Ferrario","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0215","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1753944715589717","article-title":"Differential expression of the angiotensin-(1\u201312)\/chymase axis in human atrial tissue","volume":"9","author":"Nagata","year":"2015","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0220","doi-asserted-by":"crossref","first-page":"H763","DOI":"10.1152\/ajpheart.00345.2010","article-title":"Angiotensin-(1\u201312) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus","volume":"299","author":"Arnold","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0225","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1113\/expphysiol.2012.067116","article-title":"Angiotensin-(1\u201312) in the rostral ventrolateral medullary pressor area of the rat elicits sympathoexcitatory responses","volume":"98","author":"Arakawa","year":"2013","journal-title":"Exp. Physiol."},{"issue":"1-2","key":"10.1016\/j.phrs.2017.05.020_bib0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11010-016-2801-3","article-title":"Intracellular angiotensin-(1\u201312) changes the electrical properties of intact cardiac muscle","volume":"422","author":"De Mello","year":"2016","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0235","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1152\/ajpregu.90588.2008","article-title":"Chronic immunoneutralization of brain angiotensin-(1\u201312) lowers blood pressure in transgenic (mRen2)27 hypertensive rats","volume":"297","author":"Isa","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0240","doi-asserted-by":"crossref","first-page":"H951","DOI":"10.1152\/ajpheart.01144.2010","article-title":"The hypothalamic arcuate nucleus: a new site of cardiovascular action of angiotensin-(1\u201312) and angiotensin II","volume":"300","author":"Arakawa","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0245","doi-asserted-by":"crossref","first-page":"H1184","DOI":"10.1152\/ajpheart.01114.2008","article-title":"Differential regulation of angiotensin-(1\u201312) in plasma and cardiac tissue in response to bilateral nephrectomy","volume":"296","author":"Ferrario","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"12","key":"10.1016\/j.phrs.2017.05.020_bib0250","doi-asserted-by":"crossref","first-page":"e28501","DOI":"10.1371\/journal.pone.0028501","article-title":"Chymase-dependent generation of angiotensin II from angiotensin-(1\u201312) in human atrial tissue","volume":"6","author":"Ahmad","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0255","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jash.2012.12.003","article-title":"Chymase mediates angiotensin-(1\u201312) metabolism in normal human hearts","volume":"7","author":"Ahmad","year":"2013","journal-title":"J Am Soc Hypertens"},{"issue":"11","key":"10.1016\/j.phrs.2017.05.020_bib0260","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/00004872-199311000-00001","article-title":"The chymase-angiotensin system in humans","volume":"11","author":"Husain","year":"1993","journal-title":"J. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0265","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00005344-198211000-00014","article-title":"Antihypertensive therapy with MK 421: angiotensin II\u2013renin relationships to evaluate efficacy of converting enzyme blockade","volume":"4","author":"Biollaz","year":"1982","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig","year":"2000","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib0275","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1\u20139","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"issue":"Pt 1","key":"10.1016\/j.phrs.2017.05.020_bib0280","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0285","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1139\/y02-021","article-title":"ACEH\/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors","volume":"80","author":"Turner","year":"2002","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2017.05.020_bib0290","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1042\/CS20130449","article-title":"Recent insights and therapeutic perspectives of angiotensin-(1\u20139) in the cardiovascular system","volume":"127","author":"Ocaranza","year":"2014","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0295","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/01.HYP.0000196268.08909.fb","article-title":"Angiotensin-converting enzyme 2 and angiotensin-(1\u20137): an evolving story in cardiovascular regulation","volume":"47","author":"Ferrario","year":"2006","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.phrs.2017.05.020_bib0300","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1073\/pnas.85.11.4095","article-title":"Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1\u20137) heptapeptide","volume":"85","author":"Schiavone","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0305","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1161\/HYPERTENSIONAHA.109.145839","article-title":"New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism","volume":"55","author":"Ferrario","year":"2010","journal-title":"Hypertension"},{"issue":"6 Pt 2","key":"10.1016\/j.phrs.2017.05.020_bib0310","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.HYP.19.6.692","article-title":"In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats","volume":"19","author":"Yamamoto","year":"1992","journal-title":"Hypertension"},{"issue":"18","key":"10.1016\/j.phrs.2017.05.020_bib0315","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/0024-3205(93)90108-F","article-title":"A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11","volume":"52","author":"Welches","year":"1993","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.phrs.2017.05.020_bib0320","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00004872-199107000-00008","article-title":"Evidence that prolyl endopeptidase participates in the processing of brain angiotensin","volume":"9","author":"Welches","year":"1991","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0895-7061(97)00400-7","article-title":"Characterization of angiotensin-(1\u20137) in the urine of normal and essential hypertensive subjects","volume":"11","author":"Ferrario","year":"1998","journal-title":"Am. J. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0330","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00004872-199606000-00017","article-title":"Effects of captopril related to increased levels of prostacyclin and angiotensin-(1\u20137) in essential hypertension","volume":"14","author":"Luque","year":"1996","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0335","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol. Rev."},{"issue":"33","key":"10.1016\/j.phrs.2017.05.020_bib0340","doi-asserted-by":"crossref","first-page":"24543","DOI":"10.1016\/S0021-9258(19)74499-8","article-title":"Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition","volume":"268","author":"Kambayashi","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"33","key":"10.1016\/j.phrs.2017.05.020_bib0345","doi-asserted-by":"crossref","first-page":"24539","DOI":"10.1016\/S0021-9258(19)74498-6","article-title":"Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors","volume":"268","author":"Mukoyama","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0350","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1006\/bbrc.1993.2492","article-title":"Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor","volume":"197","author":"Nakajima","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"14","key":"10.1016\/j.phrs.2017.05.020_bib0355","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1\u20137) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0360","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.116.07572","article-title":"G-protein-coupled receptor MrgD is a receptor for angiotensin-(1\u20137) involving adenylyl cyclase, cAMP, and phosphokinase a","volume":"68","author":"Tetzner","year":"2016","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0365","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0022-3565(24)36715-1","article-title":"Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries","volume":"281","author":"Li","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0370","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00005344-199808000-00005","article-title":"Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats","volume":"32","author":"Li","year":"1998","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3 Pt 2","key":"10.1016\/j.phrs.2017.05.020_bib0375","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-200103001-00007","article-title":"The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo","volume":"19","author":"Fukuhara","year":"2001","journal-title":"J. Hypertens."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0380","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(24)35282-6","article-title":"Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation","volume":"292","author":"Li","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0385","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1463-1326.2011.01377.x","article-title":"A dual ARB\/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes","volume":"13","author":"Goyal","year":"2011","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2017.05.020_bib0390","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/hr.2015.82","article-title":"Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients","volume":"38","author":"Chida","year":"2015","journal-title":"Hypertens. Res."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0395","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1185\/030079903125003017","article-title":"AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan","volume":"20","author":"Ferrario","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0400","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/2040622315596119","article-title":"The effect of angiotensin II receptor blockers on hyperuricemia","volume":"6","author":"Wolff","year":"2015","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0405","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.cr.7290083","article-title":"The angiotensin II type 1 receptor and receptor-associated proteins","volume":"11","author":"Guo","year":"2001","journal-title":"Cell Res."},{"issue":"1 Pt 2","key":"10.1016\/j.phrs.2017.05.020_bib0410","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/01.HYP.35.1.155","article-title":"Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function","volume":"35","author":"Carey","year":"2000","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib0415","doi-asserted-by":"crossref","first-page":"C1169","DOI":"10.1152\/ajpcell.00145.2008","article-title":"MAP kinase\/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides","volume":"295","author":"Gallagher","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0420","doi-asserted-by":"crossref","first-page":"H1560","DOI":"10.1152\/ajpheart.00941.2004","article-title":"Angiotensin-(1\u20137) inhibits growth of cardiac myocytes through activation of the mas receptor","volume":"289","author":"Tallant","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2017.05.020_bib0425","first-page":"1","article-title":"Cellular basis of angiotensin-(-induced augmentation of left ventricular functional performance in heart failure","author":"Zhang","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.020_bib0430","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1097\/01.hjh.0000500953.48843.41","article-title":"Sy 14-3 primary aldosteronism in resistant hypertension","volume":"34","author":"Calhoun","year":"2016","journal-title":"J. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0435","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pcad.2006.02.002","article-title":"Use of aldosterone antagonists in resistant hypertension","volume":"48","author":"Calhoun","year":"2006","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0440","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3810\/pgm.2012.01.2519","article-title":"Recent advancements in the treatment of resistant hypertension","volume":"124","author":"Clark","year":"2012","journal-title":"Postgrad. Med."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib0445","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tips.2015.03.001","article-title":"Angiotensins as therapeutic targets beyond heart disease","volume":"36","author":"Passos-Silva","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0450","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/01.CIR.92.4.825","article-title":"Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives","volume":"92","author":"Azizi","year":"1995","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.phrs.2017.05.020_bib0455","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1097\/01.ASN.0000146686.35541.29","article-title":"Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption","volume":"15","author":"Azizi","year":"2004","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"9\u201310","key":"10.1016\/j.phrs.2017.05.020_bib0460","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lfs.2009.11.020","article-title":"Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control","volume":"86","author":"Ferrario","year":"2010","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0465","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/01.CIR.103.1.148","article-title":"Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure","volume":"103","author":"Kim","year":"2001","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.phrs.2017.05.020_bib0470","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.05.020_bib0475","first-page":"1","article-title":"Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials","volume":"6","author":"Mancia","year":"2012","journal-title":"Patient Prefer Adherence"},{"issue":"15","key":"10.1016\/j.phrs.2017.05.020_bib0480","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0485","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2006.11.030","article-title":"Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species","volume":"195","author":"Doran","year":"2007","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0490","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1753944707085982","article-title":"Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study","volume":"1","author":"Stumpe","year":"2007","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0495","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.amjcard.2013.03.038","article-title":"Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris","volume":"112","author":"Ishii","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0500","doi-asserted-by":"crossref","first-page":"F1297","DOI":"10.1152\/ajprenal.00110.2010","article-title":"The ANG-(1\u20137)\/ACE2\/mas axis in the regulation of nephron function","volume":"298","author":"Ferrario","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"7653","key":"10.1016\/j.phrs.2017.05.020_bib0505","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.39548.738368.BE","article-title":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials","volume":"336","author":"Blood Pressure Lowering Treatment Trialists","year":"2008","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.phrs.2017.05.020_bib0510","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7164\/antibiotics.24.687","article-title":"Effect of pepstatin on acid proteases","volume":"24","author":"Aoyagi","year":"1971","journal-title":"J. Antibiot."},{"issue":"9545","key":"10.1016\/j.phrs.2017.05.020_bib0515","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(06)69442-7","article-title":"Oral renin inhibitors","volume":"368","author":"Staessen","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0520","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/00004872-198512000-00013","article-title":"A study of the renin inhibitor H142 in man","volume":"3","author":"Webb","year":"1985","journal-title":"J. Hypertens."},{"issue":"8 Suppl B","key":"10.1016\/j.phrs.2017.05.020_bib0525","doi-asserted-by":"crossref","first-page":"21","DOI":"10.18553\/jmcp.2007.13.s8-b.21","article-title":"Direct renin inhibition: focus on aliskiren","volume":"13","author":"Pool","year":"2007","journal-title":"J. Managed Care Pharm.: JMCP"},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0530","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.phrs.2017.05.020_bib0535","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCULATIONAHA.108.787630","article-title":"Aliskiren","volume":"118","author":"Brown","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0540","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrneph.2011.29","article-title":"Limitations of angiotensin inhibition","volume":"7","author":"Nobakht","year":"2011","journal-title":"Nat. Rev. Nephrol."},{"issue":"9","key":"10.1016\/j.phrs.2017.05.020_bib0545","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat. Clin. Pract. Nephrol."},{"issue":"7","key":"10.1016\/j.phrs.2017.05.020_bib0550","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0735-1097(01)01237-2","article-title":"Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype","volume":"37","author":"Cicoira","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.phrs.2017.05.020_bib0555","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2215\/CJN.06960712","article-title":"Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy","volume":"8","author":"Moranne","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0560","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/07435809809031866","article-title":"The AT2 receptor-mediated stimulation of adrenal catecholamine release may potentiate the AT1 receptor-mediated aldosterone secretagogue action of angiotensin-II in rats","volume":"24","author":"Mazzocchi","year":"1998","journal-title":"Endocr. Res."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0565","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000022606.52221.2F","article-title":"Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats","volume":"40","author":"Naruse","year":"2002","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0570","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1210\/en.2010-1070","article-title":"Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II type 1 receptor","volume":"152","author":"Yatabe","year":"2011","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0575","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000183912","article-title":"Elevated plasma renin activity associated with renal dysfunction","volume":"44","author":"Kehoe","year":"1986","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib0580","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1365-2796.2002.01053.x","article-title":"Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin","volume":"252","author":"Malmqvist","year":"2002","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-7061(96)00301-9","article-title":"Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients","volume":"10","author":"Alderman","year":"1997","journal-title":"Am. J. Hypertens."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0590","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","article-title":"Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker","volume":"49","author":"O'Brien","year":"2007","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0595","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","article-title":"New approaches in the treatment of hypertension","volume":"116","author":"Oparil","year":"2015","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.phrs.2017.05.020_bib0600","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","article-title":"Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats","volume":"96","author":"Menard","year":"1997","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0605","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00129784-200303060-00002","article-title":"Therapeutic potential of renin inhibitors in the management of cardiovascular disorders","volume":"3","author":"Stanton","year":"2003","journal-title":"Am. J. Cardiovasc. Drugs: Drugs Devices Other Interventions"},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0610","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/01.RES.66.4.883","article-title":"Angiotensin II-forming pathways in normal and failing human hearts","volume":"66","author":"Urata","year":"1990","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0615","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1015709617405","article-title":"Pathophysiologic and therapeutic importance of tissue ACE: a consensus report","volume":"16","author":"Dzau","year":"2002","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"16","key":"10.1016\/j.phrs.2017.05.020_bib0620","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.phrs.2017.05.020_bib0625","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2017.05.020_bib0630","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0635","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/HYPERTENSIONAHA.112.201889","article-title":"Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension","volume":"61","author":"Moniwa","year":"2013","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0640","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.113.01504","article-title":"Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies","volume":"62","author":"Rajagopalan","year":"2013","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0645","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","article-title":"Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats","volume":"52","author":"Feldman","year":"2008","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0650","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/HJH.0b013e32835e226b","article-title":"Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin","volume":"31","author":"Lange","year":"2013","journal-title":"J. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0655","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: renin-angiotensin-aldosterone system alterations","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib0660","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.113.02893","article-title":"Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition","volume":"63","author":"Balcarek","year":"2014","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0665","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MNH.0b013e328359dbed","article-title":"Proximal tubule angiotensinogen modulation of arterial pressure","volume":"22","author":"Ramkumar","year":"2013","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.phrs.2017.05.020_bib0670","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev.physiol.65.050102.085738","article-title":"Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide","volume":"65","author":"Schnermann","year":"2003","journal-title":"Annu. Rev. Physiol."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0675","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2174\/15701611113116660149","article-title":"Molecular mechanisms of renal blood flow autoregulation","volume":"12","author":"Burke","year":"2014","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0680","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1161\/01.HYP.34.6.1265","article-title":"Elements of a paracrine tubular renin-angiotensin system along the entire nephron","volume":"34","author":"Rohrwasser","year":"1999","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0685","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2165\/00002018-199615030-00005","article-title":"ACE inhibitors and the kidney. A risk-benefit assessment","volume":"15","author":"Navis","year":"1996","journal-title":"Drug Saf."},{"issue":"11","key":"10.1016\/j.phrs.2017.05.020_bib0690","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1097\/00004872-200111000-00021","article-title":"Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake","volume":"19","author":"Griffiths","year":"2001","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0695","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00004872-200403000-00026","article-title":"Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt","volume":"22","author":"Richer-Giudicelli","year":"2004","journal-title":"J. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0700","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ajh\/hpt034","article-title":"Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels","volume":"26","author":"Sealey","year":"2013","journal-title":"Am. J. Hypertens."},{"issue":"7","key":"10.1016\/j.phrs.2017.05.020_bib0705","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.2215\/CJN.08611209","article-title":"Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations","volume":"5","author":"Turgut","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol.: CJASN"},{"issue":"16","key":"10.1016\/j.phrs.2017.05.020_bib0710","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0715","first-page":"461","article-title":"Using ACE inhibitors appropriately","volume":"66","author":"Bicket","year":"2002","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.phrs.2017.05.020_bib0720","series-title":"Angiotensin","first-page":"375","article-title":"Pharmacology","author":"Gohlke","year":"2004"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0725","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00003495-199754010-00012","article-title":"A review of its pharmacology and clinical efficacy in the management of heart failure","volume":"54","author":"Davis","year":"1997","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0730","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/j.1875-9114.1998.tb03121.x","article-title":"Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors","volume":"18","author":"White","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.phrs.2017.05.020_bib0735","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijcard.2016.06.053","article-title":"The incidence of all-cause, cardiovascular and respiratory disease admission among 20,252 users of lisinopril vs. perindopril: a cohort study","volume":"219","author":"Wong","year":"2016","journal-title":"Int. J. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib0740","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/01.HYP.16.5.564","article-title":"Determinants of angiotensin II generation during converting enzyme inhibition","volume":"16","author":"Juillerat","year":"1990","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0745","doi-asserted-by":"crossref","first-page":"H2254","DOI":"10.1152\/ajpheart.00191.2001","article-title":"Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene","volume":"282","author":"Wei","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0750","doi-asserted-by":"crossref","first-page":"e15759","DOI":"10.1371\/journal.pone.0015759","article-title":"Uptake and metabolism of the novel peptide angiotensin-(1\u201312) by neonatal cardiac myocytes","volume":"6","author":"Ahmad","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0755","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/01.RES.0000084993.90444.6C","article-title":"Do studies with ACE N- and C-domain-selective inhibitors provide evidence for a non-ACE, non-chymase angiotensin II-forming pathway?","volume":"93","author":"Husain","year":"2003","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.phrs.2017.05.020_bib0760","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.96.8.4330","article-title":"RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites","volume":"96","author":"Dive","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.phrs.2017.05.020_bib0765","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0770","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.116.303641","article-title":"Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal","volume":"116","author":"Zanchetti","year":"2015","journal-title":"Circ. Res."},{"issue":"28","key":"10.1016\/j.phrs.2017.05.020_bib0775","doi-asserted-by":"crossref","first-page":"19288","DOI":"10.1074\/jbc.M602144200","article-title":"Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor","volume":"281","author":"Miura","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.phrs.2017.05.020_bib0780","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"9311","key":"10.1016\/j.phrs.2017.05.020_bib0785","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"issue":"9704","key":"10.1016\/j.phrs.2017.05.020_bib0790","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.phrs.2017.05.020_bib0795","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.phrs.2017.05.020_bib0800","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"Group","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2017.05.020_bib0805","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0895-7061(03)00904-X","article-title":"VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk","volume":"16","author":"Julius","year":"2003","journal-title":"Am. J. Hypertens."},{"issue":"16","key":"10.1016\/j.phrs.2017.05.020_bib0810","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa060838","article-title":"for the Trial of Preventing Hypertension Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker","volume":"354","author":"Julius","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.phrs.2017.05.020_bib0815","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"9386","key":"10.1016\/j.phrs.2017.05.020_bib0820","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.phrs.2017.05.020_bib0825","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.phrs.2017.05.020_bib0830","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"10.1016\/j.phrs.2017.05.020_bib0835","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.phrs.2017.05.020_bib0840","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.phrs.2017.05.020_bib0845","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0850","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00125-009-1577-3","article-title":"Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study","volume":"53","author":"Ritz","year":"2010","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib0855","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1753944716644130","article-title":"Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering","volume":"10","author":"Dusing","year":"2016","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"16","key":"10.1016\/j.phrs.2017.05.020_bib0860","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/eurheartj\/ehs108","article-title":"Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?","volume":"33","author":"Ruschitzka","year":"2012","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib0865","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1042\/CS20120089","article-title":"The intracrine renin-angiotensin system","volume":"123","author":"Kumar","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"issue":"5 Pt 1","key":"10.1016\/j.phrs.2017.05.020_bib0870","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0895-7061(03)00038-4","article-title":"Cardiac angiotensin II: an intracrine hormone?","volume":"16","author":"Re","year":"2003","journal-title":"Am. J. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0875","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jash.2011.07.001","article-title":"Noncanonical intracrine action","volume":"5","author":"Re","year":"2011","journal-title":"J. Am. Soc. Hypertens."},{"issue":"4306","key":"10.1016\/j.phrs.2017.05.020_bib0880","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/169795a0","article-title":"Isolation of a highly active mineralocorticoid from beef adrenal extract","volume":"169","author":"Grundy","year":"1952","journal-title":"Nature"},{"issue":"6699","key":"10.1016\/j.phrs.2017.05.020_bib0885","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(52)92427-6","article-title":"The effect of adrenal extract on mineral metabolism","volume":"1","author":"Tait","year":"1952","journal-title":"Lancet"},{"issue":"7240","key":"10.1016\/j.phrs.2017.05.020_bib0890","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(62)92199-2","article-title":"The effects of spironolactone and chlorthalidone on arterial pressure","volume":"1","author":"Cranston","year":"1962","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0895","first-page":"661","article-title":"Primary aldosteronism","volume":"45","author":"Conn","year":"1955","journal-title":"J. Lab. Clin. Med."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0900","first-page":"57","article-title":"Management of resistant hypertension: do not give up on medication","volume":"13","author":"Judd","year":"2014","journal-title":"Nephrol. Self Assess. Program"},{"key":"10.1016\/j.phrs.2017.05.020_bib0905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.steroids.2014.10.003","article-title":"Non renal effects of aldosterone","volume":"91","author":"Gomez-Sanchez","year":"2014","journal-title":"Steroids"},{"issue":"31","key":"10.1016\/j.phrs.2017.05.020_bib0910","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.phrs.2017.05.020_bib0915","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"27","key":"10.1016\/j.phrs.2017.05.020_bib0920","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.phrs.2017.05.020_bib0925","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0930","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0935","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.phrs.2017.05.020_bib0940","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","article-title":"Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt","volume":"75","author":"Lea","year":"2009","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0945","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.hjh.0000226205.65442.f2","article-title":"Investigation of aldosterone-synthase inhibition in rats","volume":"24","author":"Menard","year":"2006","journal-title":"J. Hypertens."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0950","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib0955","doi-asserted-by":"crossref","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","article-title":"Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?","volume":"310","author":"Chappell","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"12","key":"10.1016\/j.phrs.2017.05.020_bib0960","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11906-016-0694-x","article-title":"From ARB to ARNI in cardiovascular control","volume":"18","author":"Uijl","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0965","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail."},{"issue":"6 Pt 2","key":"10.1016\/j.phrs.2017.05.020_bib0970","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/01.HYP.26.6.1160","article-title":"Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin","volume":"26","author":"Ando","year":"1995","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib0975","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/13543784.8.1.79","article-title":"The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man","volume":"8","author":"McDowell","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"9116","key":"10.1016\/j.phrs.2017.05.020_bib0980","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","article-title":"Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators","volume":"351","author":"Cleland","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0985","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/hy1201.096569","article-title":"Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients","volume":"38","author":"Campese","year":"2001","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib0990","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1523-1755.2002.kid559.x","article-title":"Vasopeptidase inhibition and Ang-(1\u20137) in the spontaneously hypertensive rat","volume":"62","author":"Ferrario","year":"2002","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib0995","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0895-7061(02)02268-9","article-title":"Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension","volume":"15","author":"Ferrario","year":"2002","journal-title":"Am. J. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib1000","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1067\/mhj.2002.123111","article-title":"Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure","volume":"143","author":"Eisenstein","year":"2002","journal-title":"Am. Heart J."},{"issue":"8","key":"10.1016\/j.phrs.2017.05.020_bib1005","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1524-6175.2002.01506.x","article-title":"Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat","volume":"4","author":"Pickering","year":"2002","journal-title":"J. Clin. Hypertens."},{"issue":"9722","key":"10.1016\/j.phrs.2017.05.020_bib1015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.phrs.2017.05.020_bib1020","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis","volume":"18","author":"Solomon","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"9851","key":"10.1016\/j.phrs.2017.05.020_bib1025","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"Prospective comparison of, The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled triall","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib1030","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study","volume":"63","author":"Kario","year":"2014","journal-title":"Hypertension"},{"issue":"11","key":"10.1016\/j.phrs.2017.05.020_bib1035","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/jama.2015.17632","article-title":"Valsartan\/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations","volume":"315","author":"Feldman","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1050","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","article-title":"The effect of LCZ696 (sacubitril\/valsartan) on amyloid-beta concentrations in cerebrospinal fluid in healthy subjects","volume":"81","author":"Langenickel","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ejhf.687","article-title":"Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction","volume":"19","author":"Cannon","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib1060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/01.HYP.0000257145.20363.9c","article-title":"Genetic susceptibility to essential hypertension: insight from angiotensinogen","volume":"49","author":"Lalouel","year":"2007","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.HYP.0000227932.13687.60","article-title":"Genetic basis of hypertension: revisiting angiotensinogen","volume":"48","author":"Dickson","year":"2006","journal-title":"Hypertension"},{"issue":"7320","key":"10.1016\/j.phrs.2017.05.020_bib1070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature09505","article-title":"A redox switch in angiotensinogen modulates angiotensin release","volume":"468","author":"Zhou","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/ng0593-59","article-title":"A molecular variant of angiotensinogen associated with preeclampsia","volume":"4","author":"Ward","year":"1993","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1080","first-page":"662","article-title":"Molecular genetics of human hypertension: role of angiotensinogen","volume":"18","author":"Corvol","year":"1997","journal-title":"Endocr. Rev."},{"issue":"7","key":"10.1016\/j.phrs.2017.05.020_bib1085","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1073\/pnas.92.7.2735","article-title":"Genetic control of blood pressure and the angiotensinogen locus","volume":"92","author":"Kim","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib1090","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/ki.1994.444","article-title":"Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes","volume":"46","author":"Phillips","year":"1994","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib1095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-0115(93)90438-E","article-title":"Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin","volume":"49","author":"Gyurko","year":"1993","journal-title":"Regul. Pept."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib1100","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.HYP.25.3.314","article-title":"Antisense inhibition of hypertension in the spontaneously hypertensive rat","volume":"25","author":"Wielbo","year":"1995","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/01.HYP.28.1.147","article-title":"Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides","volume":"28","author":"Wielbo","year":"1996","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/01.HYP.26.1.131","article-title":"Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen","volume":"26","author":"Tomita","year":"1995","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib1115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00004872-200018060-00010","article-title":"Reduction of plasma angiotensin II to normal levels by antisense oligodeoxynucleotides against liver angiotensinogen cannot completely attenuate vascular remodeling in spontaneously hypertensive rats","volume":"18","author":"Sugano","year":"2000","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib1120","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0008-6363(99)00254-0","article-title":"Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats","volume":"44","author":"Makino","year":"1999","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1125","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1161\/01.HYP.31.5.1166","article-title":"Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats","volume":"31","author":"Makino","year":"1998","journal-title":"Hypertension"},{"issue":"6 Pt 2","key":"10.1016\/j.phrs.2017.05.020_bib1130","first-page":"H2392","article-title":"Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension","volume":"277","author":"Tang","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1135","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/nar\/19.5.1113","article-title":"Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism","volume":"19","author":"Boiziau","year":"1991","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib1140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2017.05.020_bib1145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacool. Toxicol."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib1150","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/ATVBAHA.115.306740","article-title":"Angiotensinogen exerts effects independent of angiotensin II","volume":"36","author":"Lu","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib1155","doi-asserted-by":"crossref","first-page":"F349","DOI":"10.1152\/ajprenal.00478.2014","article-title":"Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2","volume":"308","author":"Ravichandran","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1160","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1096\/fj.15-279299","article-title":"Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model","volume":"30","author":"Saigusa","year":"2016","journal-title":"FASEB J.: Off. Publ. Federation Am. Soc. Exp. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1165","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/hr.2013.155","article-title":"Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension","volume":"37","author":"Olearczyk","year":"2014","journal-title":"Hypertens. Res.: Off. J. Jpn. Soc. Hypertens."},{"key":"10.1016\/j.phrs.2017.05.020_bib1170","doi-asserted-by":"crossref","DOI":"10.1161\/hyp.64.suppl_1.666","article-title":"RNAi therapeutics targeting human angiotensinogen (hAGT) ameliorate preeclamptic sequelae in an established transgenic rodent model for preeclampsia","volume":"64","author":"Haase","year":"2014","journal-title":"Hypertension"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2017.05.020_bib1175","article-title":"Liver-specific antisense inhibition of angiotensinogen reduced BP in a hypertensive rat model resistant to standard RAS inhibition","volume":"66","author":"Mullick","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.05.020_bib1180","doi-asserted-by":"crossref","DOI":"10.1161\/hyp.60.suppl_1.A627","article-title":"Antisense inhibition of angiotensinogen reduces BP in normotensive sprague-dawley rats and effectively eliminates RAS-dependent BP control In hypertensive SHR rats","volume":"60","author":"Mullick","year":"2012","journal-title":"Hypertension"},{"issue":"6891","key":"10.1016\/j.phrs.2017.05.020_bib1185","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib1190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tips.2004.04.001","article-title":"ACE2: from vasopeptidase to SARS virus receptor","volume":"25","author":"Turner","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.phrs.2017.05.020_bib1195","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1440-1681.12059","article-title":"Role of angiotensin AT(2) receptors in natriuresis: intrarenal mechanisms and therapeutic potential","volume":"40","author":"Carey","year":"2013","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"15","key":"10.1016\/j.phrs.2017.05.020_bib1200","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1042\/CS20160243","article-title":"Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease","volume":"130","author":"Chow","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib1205","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s10753-015-0146-9","article-title":"Stimulation of the angiotensin II AT2 receptor is anti-inflammatory in human lipopolysaccharide-activated monocytic cells","volume":"38","author":"Menk","year":"2015","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib1210","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCRESAHA.115.304110","article-title":"AT(2) receptor activation induces natriuresis and lowers blood pressure","volume":"115","author":"Kemp","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2017.05.020_bib1215","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.coph.2015.01.004","article-title":"Angiotensin type 2 receptors: blood pressure regulation and end organ damage","volume":"21","author":"Sumners","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib1220","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/0929867321666141106113018","article-title":"New antihypertensive drugs under development","volume":"22","author":"Tamargo","year":"2015","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1225","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.phrs.2017.05.020_bib1230","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.phrs.2017.05.020_bib1235","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/13543776.2016.1179283","article-title":"Therapeutic uses for angiotensin-(1\u20137)","volume":"26","author":"Machado-Silva","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/cs0410001","article-title":"The haemodynamic consequences of adaptive structural changes of the resistance vessels in hypertension","volume":"41","author":"Folkow","year":"1971","journal-title":"Clin. Sci."},{"issue":"45","key":"10.1016\/j.phrs.2017.05.020_bib1245","first-page":"5165","article-title":"[Hemodynamic consequences of adaptive reconstruction of resistance vessels]","volume":"68","author":"Folkow","year":"1971","journal-title":"Lakartidningen"},{"issue":"3","key":"10.1016\/j.phrs.2017.05.020_bib1250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jash.2007.11.001","article-title":"Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors","volume":"2","author":"Smith","year":"2008","journal-title":"J. Am. Soc. Hypertens."},{"issue":"Suppl. A","key":"10.1016\/j.phrs.2017.05.020_bib1255","first-page":"15A","article-title":"Vascular changes in hypertension in response to drug treatment: effects of angiotensin receptor blockers","volume":"18","author":"Schiffrin","year":"2002","journal-title":"Can. J. Cardiol."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1260","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00041552-200109000-00011","article-title":"Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?","volume":"10","author":"Schiffrin","year":"2001","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"1","key":"10.1016\/j.phrs.2017.05.020_bib1265","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00000441-200107000-00002","article-title":"Small artery remodeling in hypertension: can it be corrected?","volume":"322","author":"Schiffrin","year":"2001","journal-title":"Am. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib1270","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.peptides.2012.09.016","article-title":"Subcellular characteristics of functional intracellular renin-angiotensin systems","volume":"38","author":"Abadir","year":"2012","journal-title":"Peptides"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2017.05.020_bib1275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.regpep.2004.04.004","article-title":"Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy","volume":"120","author":"Baker","year":"2004","journal-title":"Regul. Pept."},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1280","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.tem.2007.05.001","article-title":"The intracellular renin-angiotensin system: a new paradigm","volume":"18","author":"Kumar","year":"2007","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2017.05.020_bib1285","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0022-2828(89)90772-4","article-title":"The cellular biology of angiotensin: paracrine, autocrine and intracrine actions in cardiovascular tissues","volume":"21","author":"Re","year":"1989","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.phrs.2017.05.020_bib1290","article-title":"Angiotensinogen import in isolated proximal tubules: evidence for mitochondrial trafficking and uptake","volume":"00246","author":"Wilson","year":"2016","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"10","key":"10.1016\/j.phrs.2017.05.020_bib1295","doi-asserted-by":"crossref","first-page":"e76992","DOI":"10.1371\/journal.pone.0076992","article-title":"Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2. Lewis rats","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib1300","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1470320313515039","article-title":"Nuclear expression of renin-angiotensin system components in NRK-52E renal epithelial cells","volume":"16","author":"Alzayadneh","year":"2015","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"issue":"20","key":"10.1016\/j.phrs.2017.05.020_bib1305","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2017.05.020_bib1310","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/ajh\/hps090","article-title":"Predominance of AT(1) blockade over mas-mediated angiotensin-(1\u20137) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2. Lewis rats","volume":"26","author":"Varagic","year":"2013","journal-title":"Am. J. Hypertens."},{"issue":"26","key":"10.1016\/j.phrs.2017.05.020_bib1315","doi-asserted-by":"crossref","first-page":"17173","DOI":"10.1016\/S0021-9258(19)47355-9","article-title":"Cloning of the gene and cDNA for human heart chymase","volume":"266","author":"Urata","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib1320","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1172\/JCI39345","article-title":"Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents","volume":"120","author":"Wei","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib1325","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1254\/fpj.124.77","article-title":"Chymase-derived angiotensin II and arrhythmias after myocardial infarction","volume":"124","author":"Jin","year":"2004","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib1330","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1124\/jpet.103.061465","article-title":"An antiarrhythmic effect of a chymase inhibitor after myocardial infarction","volume":"309","author":"Jin","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2017.05.020_bib1335","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0008-6363(03)00535-2","article-title":"Impact of chymase inhibitor on cardiac function and survival after myocardial infarction","volume":"60","author":"Jin","year":"2003","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib1340","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/1440-1681.12549","article-title":"Improvement of cardiovascular remodelling by chymase inhibitor","volume":"43","author":"Takai","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2017.05.020_bib1345","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/14728222.2011.555401","article-title":"Targets of chymase inhibitors","volume":"15","author":"Takai","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.phrs.2017.05.020_bib1350","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.tips.2004.08.007","article-title":"Chymase as a novel target for the prevention of vascular diseases","volume":"25","author":"Takai","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"1-3","key":"10.1016\/j.phrs.2017.05.020_bib1355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2004.08.040","article-title":"Therapeutic applications of chymase inhibitors in cardiovascular diseases and fibrosis","volume":"501","author":"Takai","year":"2004","journal-title":"Eur. J. Pharmacol."},{"issue":"9054","key":"10.1016\/j.phrs.2017.05.020_bib1360","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"issue":"9215","key":"10.1016\/j.phrs.2017.05.020_bib1365","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2013the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"issue":"9644","key":"10.1016\/j.phrs.2017.05.020_bib1370","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"Yusuf","year":"2008","journal-title":"Lancet"},{"issue":"9335","key":"10.1016\/j.phrs.2017.05.020_bib1375","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817303456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817303456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T21:33:12Z","timestamp":1750282392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817303456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":275,"alternative-id":["S1043661817303456"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.05.020","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}